rue Paul Vatine
12th Floor ZI des Quatre Chevaliers
Périgny 17180
France
33 5 46 28 62 58
https://www.valbiotis.com
Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein:
Nom | Titre | Payer | Exercé | Année de naissance |
---|---|---|---|---|
Mr. Sebastien Peltier HDR, Ph.D. | Co-Founder, Member of the Management Board & CEO | 318k | S.O. | 1978 |
Mr. Sebastien Bessy | COO & Member of the Management Board | 213k | S.O. | S.O. |
Mr. Pascal Sirvent Ph.D. | CSO & Member of the Management Board | 241k | S.O. | S.O. |
Ms. Murielle Cazaubiel | CMO & Member of the Management Board | 205k | S.O. | S.O. |
Mr. Stanislas Sordet | CFO & Member of Management Board | S.O. | S.O. | S.O. |
Ms. Charlotte Jezequel | CPO & Member of Management Board | S.O. | S.O. | S.O. |
Dr. Josep Infesta | Head of Global Business Development | S.O. | S.O. | S.O. |
Valbiotis SA engages in the research and development of health nutrition products to prevent and control metabolic and cardiovascular diseases in France. The company develops TOTUM-63 for the treatment of type 2 diabetes; TOTUM-070, which is in Phase II/III clinical trials to treat hypercholesterolemia; and TOTUM-854 that is in Phase II/III clinical trials for arterial hypertension. It also develops TOTUM-448 for the treatment of patient with MASLD. It has a strategic partnership with Nestlé Health Science. Valbiotis SA was incorporated in 2014 and is headquartered in Périgny, France.
L’ISS Governance QualityScore de Valbiotis SA en date du S.O. est S.O.. Les scores principaux sont Audit : S.O.; Société : S.O.; Droits des actionnaires : S.O.; Compensation : S.O..